Back to top

Image: Bigstock

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Read MoreHide Full Article

In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $70.82, marking a -0.32% move from the previous day. This move lagged the S&P 500's daily gain of 1.13%. Elsewhere, the Dow gained 0.74%, while the tech-heavy Nasdaq added 0.87%.

Prior to today's trading, shares of the biopharmaceutical company had gained 5.18% over the past month. This has lagged the Medical sector's gain of 5.72% and outpaced the S&P 500's gain of 2.65% in that time.

Investors will be hoping for strength from Bristol Myers Squibb as it approaches its next earnings release, which is expected to be April 29, 2022. On that day, Bristol Myers Squibb is projected to report earnings of $1.93 per share, which would represent year-over-year growth of 10.92%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.33 billion, up 2.28% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.79 per share and revenue of $46.88 billion. These totals would mark changes of +3.73% and +1.07%, respectively, from last year.

Investors should also note any recent changes to analyst estimates for Bristol Myers Squibb. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.08% higher. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold).

In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 9.12. This represents a discount compared to its industry's average Forward P/E of 21.86.

Meanwhile, BMY's PEG ratio is currently 1.35. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.16 at yesterday's closing price.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Bristol Myers Squibb Company (BMY) - free report >>

Published in